JY
CATX icon

Jeff Yass’s Perspective Therapeutics CATX Stock Holding History

Jeff Yass’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-51,100
Closed -$213K – 13456
2026
Q1 		$213K Buy
+51,100
New +$216K ﹤0.01% 11562

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Jeff Yass's CATX Position: Q2 2026 in Review

Jeff Yass reduced its Perspective Therapeutics (CATX) stake by 84% in Q2 2026, selling an estimated $593K and leaving 29,789 shares worth $102K. The position accounts for ﹤0.01% of the portfolio, ranked #12486.

Jeff Yass first reported a position in CATX in Q2 2014 and has held it in 28 quarters since. The position peaked at $778K in Q1 2026. 131 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Jeff Yass held 29,789 shares of Perspective Therapeutics worth $102K as of Q2 2026.
  • Jeff Yass sold 156,841 Perspective Therapeutics shares in Q2 2026, an estimated $593K.
  • Perspective Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12486 holding.
  • Jeff Yass first reported a position in Perspective Therapeutics in Q2 2014 and has held it in 28 quarters since.
  • Jeff Yass's Perspective Therapeutics position peaked at $778K in Q1 2026.
  • 131 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.